Table 8.

Frequencies of virus-specific, MHC class I- and II-restricted CTLp in BAL and spleen

Day post-challengeTreatmentaReciprocal CTLp frequencyb
ImmunizationChallengeSourceClass IClass II
3B1B1SPLc 53,80085,300
B1CP52SPL33,50056,300
CP52B1SPL33,20068,200
CP52CP52SPL88,200d >106 d
VeroB1SPL55,500>106 
VeroCP52SPL79,900d >106 d
B1B1BAL42,20078,400
B1CP52BAL41,80052,200
CP52B1BAL21,50072,600
CP52CP52BAL77,50081,900
VeroB1BAL45,400454,600
VeroCP52BAL112,300d >106 d
5B1B1SPL9,40020,300
B1CP52SPL6,50033,400
CP52B1SPL15,50022,700
CP52CP52SPL13,00014,500
VeroB1SPL7,90062,100
VeroCP52SPL13,00073,800d
B1B1BAL8,2007,700
B1CP52BAL11,40028,900d
CP52B1BAL6,40019,300
CP52CP52BAL13,3005,600
VeroB1BAL10,50021,700
VeroCP52BAL45,400d 42,200d
  • a Mice were immunized and/or challenged with 104 PFU of B1 or CP52.

  • b Estimated by using linear regression and 95% confidence intervals about the slope of the regression line, plotting the number of cells versus the number nonresponding cultures. The 95% confidence intervals were used to determine significance, which is indicated by P < 0.05 %.

  • c SPL, spleen.

  • d Indicates a statistically significant difference (P < 0.05%) of CTLp frequencies between groups for the same MHC-restricted target cell.